What Happened

Corvus Pharmaceuticals reported a Q2 2026 net loss of $18.0M, up from $8.0M YoY, due to increased soquelitinib clinical trial costs. The company has $215.2M in cash, including $189.4M from a January financing, extending runway to Q2 2028. A $5.0M equity investment was made in Angel Pharmaceuticals as part of a $13.5M financing round.

Who Is Affected

Clinical research organizations and trial service providers supporting Corvus' Phase 3 PTCL and Phase 2 atopic dermatitis trials. Angel Pharmaceuticals' expanded collaboration with Corvus creates new vendor opportunities in China. NIAID researchers continue ALPS collaboration work.

Market Impact

• Soquelitinib's Phase 1 atopic dermatitis data presented at SID builds credibility for immunology applications
• 49% stake in Angel Pharma positions Corvus for China market access
• High short interest (7.49% average move on earnings) indicates volatility potential

What to Watch

Enrollment progress in Phase 3 PTCL and Phase 2 atopic dermatitis trials through 2026. Planned studies in hidradenitis suppurativa and asthma launching late 2026. Angel Pharma's Phase 1b/2 atopic dermatitis trial in China.

Related coverage

• Trevi initiates chronic-cough trial targeting 2–3M U.S. patients
• Ollin Biosciences to Present OLN324 Data for DME and wAMD at ASRS 2026
• Cadrenal Therapeutics' CAD-1005 shows >25% reduction in HIT thrombotic events
• LEQEMBI subcutaneous autoinjector shows similar efficacy and safety to IV in Alzheimer's